GlassScriptPhysician profile
Mohammed A Islam
NPI 1114938461
$1,533.99
in general payments reported to CMS, 2019-2025
17 companies · $202 in 2025
The $202 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $887 · 2020: $126 · 2021: $65.66 · 2022: $55.21 · 2023: $121 · 2024: $76.50 · 2025: $202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $399.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $231.44 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $207.39 | 2019-2024 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $178.22 | 2019-2020 | |
| Smith+Nephew, INC. | $129.47 | 2019 | |
| Novo Nordisk INC | $128.07 | 2023-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $109.87 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $107.16 | 2019-2023 | Verquvo, Steglatro |
| Janssen Pharmaceuticals, INC | $89.51 | 2021-2025 | Invega Sustenna |
| Xeris Pharmaceuticals, INC. | $79.04 | 2023-2025 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.70 | 2019-2024 | Jardiance |
| Ge Healthcare | $61.75 | 2019 | |
| Pfizer INC. | $45.26 | 2022-2025 | |
| Amgen INC. | $32.47 | 2023 | Otezla, Repatha |
| Seqirus USA INC | $26.71 | 2019-2020 | |
| Amarin Pharma, INC. | $14.99 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $13.66 | 2019 | |
| Athena Bioscience, LLC | $10.28 | 2023 | Nexiclon Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Islam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.